| Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial.Lancet Gastroenterol Hepatol | PMID 34798039无 PMCID | 2022-Feb | 0.85 | The study is a Phase III randomized controlled trial for ulcerative colitis (a non-malignant inflammatory bowel disease), not a human malignant neoplasm. Furthermore, the primary and key secondary endpoints are remission (a categorical, non-time-to-event outcome), with no time-to-event efficacy endpoint (e.g., OS, PFS, DFS) or associated analysis (Kaplan-Meier, HR) reported. | 待处理 |
| Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial.Lancet Respir Med | PMID 34800364PMC8598212 | 2022-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Phase III, Randomized, Double-blind, Placebo controlled trial of Efficacy, Safety and Tolerability of Antiviral drug Umifenovir vs Standard care of therapy in non-severe COVID-19 patients.Int J Infect Dis | PMID 34801738PMC8603331 | 2022-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Prognostic significance of ethnicity and age in advanced stage epithelial ovarian cancer: An NRG oncology/gynecologic oncology group study.Gynecol Oncol | PMID 34857397PMC9400113 | 2022-Feb | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial.Breast Cancer Res Treat | PMID 34860318PMC8831286 | 2022-Feb | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Patient reported outcomes for cisplatin and radiation followed by carboplatin/paclitaxel versus carboplatin/paclitaxel for locally advanced endometrial carcinoma: An NRG oncology study.Gynecol Oncol | PMID 34903380PMC9019849 | 2022-Feb | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study.Gynecol Oncol | PMID 34906376无 PMCID | 2022-Feb | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial.Ann Rheum Dis | PMID 34911706PMC8762015 | 2022-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Pharmacological Inhibition of CETP (Cholesteryl Ester Transfer Protein) Increases HDL (High-Density Lipoprotein) That Contains ApoC3 and Other HDL Subspecies Associated With Higher Risk of Coronary Heart Disease.Arterioscler Thromb Vasc Biol | PMID 34937388PMC8785774 | 2022-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Consistently High Agreement Between Independent Raters of Niemann-Pick Type C1 Clinical Severity Scale in Phase 2/3 Trial.Pediatr Neurol | PMID 34952292PMC8900058 | 2022-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.Gynecol Oncol | PMID 34952708无 PMCID | 2022-Feb | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| The added value of multi-state modelling in a randomized controlled trial: The HOVON 102 study re-analyzed.Cancer Med | PMID 34953042PMC8817075 | 2022-Feb | 0.75 | The study is a re-analysis of an original phase III RCT, not the primary result report itself. Furthermore, the abstract does not explicitly provide the required primary/key secondary time-to-event endpoint (e.g., OS, PFS, DFS) with Kaplan-Meier or HR data suitable for digitization. | 待处理 |
| Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial.Lancet Diabetes Endocrinol | PMID 34953531无 PMCID | 2022-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Long-term cannabidiol treatment for seizures in patients with tuberous sclerosis complex: An open-label extension trial.Epilepsia | PMID 34957550PMC9305454 | 2022-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Clinical application of protein-enhanced diet using mealworms in patients undergoing hepato-pancreato-biliary surgery.Nutrition | PMID 34965499无 PMCID | 2022-Feb | 0.95 | The study is a randomized Phase III trial but it is not oncology-focused (it evaluates a dietary intervention for malnutrition in surgical patients), it does not involve a drug intervention, and it lacks a time-to-event primary or secondary efficacy endpoint. The endpoints are body composition and immune cell activity. | 待处理 |
| Identifying optimal clinical trial candidates for locoregionally advanced nasopharyngeal carcinoma: Analysis of 9468 real-world cases and validation by two phase 3 multicentre, randomised controlled trial.Radiother Oncol | PMID 34971660无 PMCID | 2022-Feb | 0.80 | The record is a methodological study that uses data from two Phase III trials (NCT01245959, NCT01872962) to validate a risk stratification model. It is not the original formal-result report of a single drug trial, and the specific drug interventions are not described in the provided abstract. | 待处理 |
| Pembrolizumab versus chemotherapy for patients with esophageal squamous cell carcinoma enrolled in the randomized KEYNOTE-181 trial in Asia.ESMO Open | PMID 34973513PMC8764510 | 2022-Feb | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Dosimetric impact of interfraction prostate and seminal vesicle volume changes and rotation: A post-hoc analysis of a phase III randomized trial of MRI-guided versus CT-guided stereotactic body radiotherapy.Radiother Oncol | PMID 34979212无 PMCID | 2022-Feb | 0.95 | The report is a post-hoc dosimetric analysis from a phase III randomized trial evaluating MRI-guided versus CT-guided stereotactic body radiotherapy for prostate cancer. While it meets the criteria for being oncological, human, randomized, and phase III, it does not report any survival, progression, recurrence, death, hazard, time-to-event, or closely related efficacy outcomes. The outcomes reported are dosimetric (e.g., volume changes, rotation angles, V100%, V95%), which are not eligible efficacy outcomes for this adjudication. | 待处理 |
| Benefits of immunonutrition in patients with head and neck cancer receiving chemoradiation: A phase II randomized, double-blind study.Clin Nutr | PMID 35007812无 PMCID | 2022-Feb | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Efficacy and safety of linaclotide in patients with irritable bowel syndrome with constipation: Chinese sub-cohort analysis of a phase III, randomized, double-blind, placebo-controlled trial.J Dig Dis | PMID 35019221PMC9314117 | 2022-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial.Lancet Oncol | PMID 35030335无 PMCID | 2022-Feb | 1.00 | 命中用户提供的消化道肿瘤阳性参考集。 | 待处理 |
| Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study.Lancet Haematol | PMID 35032434无 PMCID | 2022-Feb | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial.Lancet Oncol | PMID 35032437PMC9479564 | 2022-Feb | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial.Lancet Oncol | PMID 35038432无 PMCID | 2022-Feb | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial.Lancet Oncol | PMID 35038433PMC8903071 | 2022-Feb | 1.00 | 命中用户提供的消化道肿瘤阳性参考集。 | 待处理 |
| Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-cell lung cancer.ESMO Open | PMID 35042152PMC8777286 | 2022-Feb | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19.Diabetes Metab Syndr | PMID 35051686PMC8755553 | 2022-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Tailoring maintenance chemotherapy upon response to induction chemotherapy as compared with pemetrexed continuation maintenance in advanced non-squamous NSCLC patients: Results of the IFCT-GFPC-1101 multicenter randomized phase III trial.Lung Cancer | PMID 35051725无 PMCID | 2022-Feb | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials.Lancet Neurol | PMID 35065036无 PMCID | 2022-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Does "wearing off" of efficacy occur in galcanezumab-treated patients at the end of the monthly treatment cycle? Post hoc analyses of four phase III randomized trials.Headache | PMID 35076090PMC9306502 | 2022-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study.RMD Open | PMID 35121639PMC8819784 | 2022-Feb | 0.95 | The record is for a rheumatoid arthritis trial, which is non-oncology. While it is a randomized Phase III drug trial with results, it fails the oncology criterion. | 待处理 |
| Reducing the physical, social, and emotional impact of episodic migraine: Results from erenumab STRIVE and ARISE phase III randomized trials.Headache | PMID 35137394无 PMCID | 2022-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Safety Profile of Bremelanotide Across the Clinical Development Program.J Womens Health (Larchmt) | PMID 35147466无 PMCID | 2022-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial.J Immunother Cancer | PMID 35190375PMC8862451 | 2022-Feb | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Randomized Trial of Molnupiravir or Placebo in Patients Hospitalized with Covid-19.NEJM Evid | PMID 38319178无 PMCID | 2022-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Phase 2/3 Trial of Molnupiravir for Treatment of Covid-19 in Nonhospitalized Adults.NEJM Evid | PMID 38319179无 PMCID | 2022-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A randomized trial assessing the efficacy, immunogenicity, and safety of vaccination with live attenuated varicella zoster virus-containing vaccines: ten-year follow-up in Russian children.Hum Vaccin Immunother | PMID 34435933PMC9067519 | 2022-Jan-31 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial.Lancet | PMID 35065705PMC8776284 | 2022-Jan-29 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the VISIBLE 2 Randomised Trial.J Crohns Colitis | PMID 34402887PMC8797168 | 2022-Jan-28 | 0.95 | The study is a randomized, phase III trial of a drug (vedolizumab) in Crohn's disease, an inflammatory bowel disease, not a malignant neoplasm. The primary endpoint is clinical remission (a categorical binary endpoint), not a time-to-event endpoint like OS or PFS. No Kaplan-Meier curves, hazard ratios, or other time-to-event outcomes are mentioned in the abstract. | 待处理 |
| Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE.Blood | PMID 34269818PMC8796656 | 2022-Jan-27 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.N Engl J Med | PMID 34904799PMC11702892 | 2022-Jan-27 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Vitamin D and marine omega 3 fatty acid supplementation and incident autoimmune disease: VITAL randomized controlled trial.BMJ | PMID 35082139PMC8791065 | 2022-Jan-26 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| VEGF-A, VEGFR1 and VEGFR2 single nucleotide polymorphisms and outcomes from the AGITG MAX trial of capecitabine, bevacizumab and mitomycin C in metastatic colorectal cancer.Sci Rep | PMID 35075138PMC8786898 | 2022-Jan-24 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Factors Associated with Work-Related Burnout among Corporate Employees Amidst COVID-19 Pandemic.Int J Environ Res Public Health | PMID 35162319PMC8835145 | 2022-Jan-24 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| The Activin/FLRG Pathway Associates with Poor COVID-19 Outcomes in Hospitalized Patients.Mol Cell Biol | PMID 34723652PMC8773081 | 2022-Jan-20 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-IIIA Non-Small-Cell Lung Cancer With EGFR Mutation (IMPACT).J Clin Oncol | PMID 34726958无 PMCID | 2022-Jan-20 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA).J Clin Oncol | PMID 34843406无 PMCID | 2022-Jan-20 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Prospective Phase II Open-Label Randomized Controlled Trial to Compare Mandibular Preservation in Upfront Surgery With Neoadjuvant Chemotherapy Followed by Surgery in Operable Oral Cavity Cancer.J Clin Oncol | PMID 34871101无 PMCID | 2022-Jan-20 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03).J Clin Oncol | PMID 34874182PMC10476784 | 2022-Jan-20 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection.N Engl J Med | PMID 35045228无 PMCID | 2022-Jan-20 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |